Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus

DOI: 10.1023/a:1010994022294
Pharmaceutical Research, 2001, 18, 1071-80.

#	Paper	IF	Citations
123	A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro. **2001**, 46, 117-23		25
122	Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. *Pharmaceutical Research*, **2002**, 19, 1091-6	4.5	72
121	The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective. **2003**, 43, 443-469		191
120	The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. **2003**, 31, 815-32		667
119	Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. **2003**, 31, 439-46		104
118	A method for identification of inhibition mechanism and estimation of Ki in in vitro enzyme inhibition study. **2003**, 31, 1456-7		5
117	Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. *Drug Metabolism and Pharmacokinetics*, **2003**, 18, 128-38	2.2	38
116	Evaluation of methods for predicting drug-drug interactions by Monte Carlo simulation. *Drug Metabolism and Pharmacokinetics*, **2003**, 18, 121-7	2.2	21
115	Quantitative prediction of the in vivo inhibition of diazepam metabolism by omeprazole using rat liver microsomes and hepatocytes. **2004**, 32, 572-80		21
114	Metabolic screening in vitro: metabolic stability, CYP inhibition and induction. **2004**, 1, 365-72		41
113	Simulation models for drug disposition and drug interactions. **2004**, 2, 38-45		21
112	Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. **2005**, 30, 275-86		22
111	Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. **2005**, 33, 500-7		73
110	Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. **2005**, 33, 1211-9		84
109	Animal models of xenobiotic receptors in drug metabolism and diseases. **2005**, 400, 598-618		26
108	High-throughput in vitro profiling assays: lessons learnt from experiences at Novartis. **2006**, 2, 823-33		28
107	In vitro methods in human drug biotransformation research: implications for cancer chemotherapy. **2006**, 20, 135-53		30

106	The use of wireless laptop computers for computer-assisted learning in pharmacokinetics. **2006**, 70, 4		5
105	The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. **2006**, 62, 512-26		93
104	Interspecies pharmacokinetics and in vitro metabolism of SQ109. **2006**, 147, 476-85		75
103	Characterization of the cytochrome P450 enzymes and enzyme kinetic parameters for metabolism of BVT.2938 using different in vitro systems. **2006**, 40, 1121-30		10
102	Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. **2006**, 34, 702-8		27
101	Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. **2007**, 35, 1232-8		61
100	The conduct of drug metabolism studies considered good practice (II): in vitro experiments. **2007**, 8, 822-9		200
99	The metabolism of the 5HT3 antagonists ondansetron, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes. *Xenobiotica*, **2007**, 37, 832-54	2	17
98	Evaluation of 3-O-methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes. **2007**, 35, 841-7		7
97	A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data. **2007**, 35, 79-85		55
96	The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery setting. **2007**, 35, 381-5		30
95	The metabolism of the 5HT3 antagonists, ondansetron, alosetron and GR87442 II: investigation into the in vitro methods used to predict the in vivo hepatic clearance of ondansetron, alosetron and GR87442 in the rat, dog and human. *Xenobiotica*, **2007**, 37, 855-69	2	1
94	Physiologically-Based Models to Predict Human Pharmacokinetic Parameters. **2007**, 867-884		
93	In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. **2007**, 3, 321-9		52
92	Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. *Xenobiotica*, **2007**, 37, 1196-224	2	150
91	The Intersection of Strategy and Drug Research. **2007**, 1-84		2
90	In vitro assessment of cytochrome P450 inhibition: strategies for increasing LC/MS-based assay throughput using a one-point IC(50) method and multiplexing high-performance liquid chromatography. **2007**, 96, 2485-93		39
89	Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. **2007**, 21, 635-43		75

88	Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. **2007**, 63, 477-87		19
87	Diclofenac hydroxylation in monkeys: efficiency, regioselectivity, and response to inhibitors. **2007**, 73, 880-90		15
86	Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?. **2007**, 168, 51-65		67
85	The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6. **2007**, 63, 345-53		20
84	The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. *Pharmaceutical Research*, **2008**, 25, 1891-901	4.5	93
83	An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC-MS/MS end-point. **2008**, 48, 92-9		57
82	Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. **2008**, 10, 391-400		104
81	Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. **2008**, 58, 206-14		51
80	In silico modeling of nonspecific binding to human liver microsomes. **2008**, 36, 2130-5		55
79	In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. **2009**, 37, 2045-54		51
78	Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. *Drug Metabolism and Pharmacokinetics*, **2009**, 24, 500-10	2.2	28
77	An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes. **2009**, 37, 1922-30		16
76	Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. **2009**, 37, 1793-6		123
75	Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. **2009**, 37, 1658-66		166
74	Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolism. **2009**, 98, 763-71		12
73	Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function. **2009**, 85, 319-26		26
72	The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. **2009**, 37, 1355-70		242
71	Drug–Drug Interactions: Screening for Liability and Assessment of Risk. **2009**, 165-196		

70	Theoretical considerations on quantitative prediction of drug-drug interactions. *Drug Metabolism and Pharmacokinetics*, **2010**, 25, 48-61	2.2	20
69	Physiologically Based Pharmacokinetic Modeling. **2010**, 1		1
68	Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance. *Journal of Pharmacy and Pharmacology*, **2007**, 59, 803-28	4.8	55
67	Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. **2010**, 125, 230-48		70
66	Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. **2010**, 30, 136-43		23
65	Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine. **2010**, 70, 537-46		10
64	Microsomal cytochrome p450-mediated metabolism of protopanaxatriol ginsenosides: metabolite profile, reaction phenotyping, and structure-metabolism relationship. **2010**, 38, 1731-9		45
63	Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin. *Xenobiotica*, **2010**, 40, 807-16	2	32
62	Hepatic drug-metabolizing enzyme induction and implications for preclinical and clinical risk assessment. **2010**, 38, 799-809		18
61	Assessment of in silico models for fraction of unbound drug in human liver microsomes. **2010**, 6, 533-42		25
60	Human Biotransformation. **2010**, 1-77		7
59	The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update. **2010**, 6, 1215-30		10
58	Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions. **2011**, 39, 2381-6		48
57	Cytochrome P450 CYP3A in marsupials: cloning and characterisation of the second identified CYP3A subfamily member, isoform 3A78 from koala (Phascolarctos cinereus). **2011**, 154, 367-76		4
56	Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. **2011**, 11, 400-11		58
55	Physiologically-based pharmacokinetics in drug development and regulatory science. *Annual Review of Pharmacology and Toxicology*, **2011**, 51, 45-73	17.9	472
54	Architecture of the drug-drug interaction network. **2011**, 36, 135-43		10
53	In vitro inhibitory effects of Wen-pi-tang-Hab-Wu-ling-san on human cytochrome P450 isoforms. **2011**, 36, 496-503		5

52	Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. **2011**, 43, 89-98		44
51	A refined cytochrome P540 IC□shift assay for reliably identifying CYP3A time-dependent inhibitors. **2011**, 39, 1054-7		11
50	Assessment of reactive metabolites in drug-induced liver injury. **2011**, 34, 1879-86		10
49	WITHDRAWN: Cytochrome P450 CYP3A in marsupials: Characterisation of the first identified CYP3A subfamily member, isoform 3A70 from Eastern grey kangaroo (Macropus giganteus). **2011**,		
48	In vitro metabolism of the mycotoxin enniatin B in different species and cytochrome p450 enzyme phenotyping by chemical inhibitors. **2011**, 39, 1768-76		33
47	Pharmacokinetic-pharmacodynamic modeling of rifampicin-mediated Cyp3a11 induction in steroid and xenobiotic X receptor humanized mice. **2011**, 337, 75-82		9
46	Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. *Xenobiotica*, **2011**, 41, 851-62	2	7
45	The Potential of In Silico and In Vitro Approaches to Predict In Vivo Drug□Drug Interactions and ADMET/TOX Properties. **2012**, 307-329		
44	High-throughput screening of inhibitory effects of Bo-yang-hwan-o-tang on human cytochrome P450 isoforms in vitro using UPLC/MS/MS. **2012**, 28, 1197-201		6
43	In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective □-adrenoceptor agonist. *Xenobiotica*, **2012**, 42, 1187-96	2	33
42	Technical Challenges and Recent Advances of Implementing Comprehensive ADMET Tools in Drug Discovery. **2012**, 129-159		1
41	ADME in Drug Discovery. **2013**, 3-30		5
40	Simultaneous determination of multiple CYP inhibition constants using a cocktail-probe approach. *Methods in Molecular Biology*, **2013**, 987, 11-23	1.4	5
39	Metabolism Studies In Vitro and In Vivo. **2013**, 1053-1094		2
38	Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia. **2013**, 10, 3067-75		55
37	In vitro approaches to investigate cytochrome P450 activities: update on current status and their applicability. **2013**, 9, 1097-113		10
36	Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase. **2013**, 41, 24-9		34
35	Time Course of the Changes in Novel Trioxane Antimalarial 99/411 Pharmacokinetics upon Antiepileptic Drugs Co-Administration in SD Rats. **2014**, 2014, 756965		2

34	Metabolism of the hepatotoxic compound sophoraflavanone G in rat liver microsomes. **2014**, 79, T1462-8		5
33	Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD. **2014**, 9, 1965-73		34
32	Inhibition of human cytochrome P450 enzymes by hops (Humulus lupulus) and hop prenylphenols. **2014**, 53, 55-61		30
31	Reaction Phenotyping. **2015**, 1-26		1
30	Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. **2015**, 55, 168-78		24
29	Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling. **2015**, 11, 557-72		16
28	The Reliability of Estimating Ki Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding IC50 Values: A Retrospective Analysis of 343 Experiments. **2015**, 43, 1744-50		26
27	Effects of Guanxinning injection on rat cytochrome P450 isoforms activities in vivo and in vitro. *Xenobiotica*, **2015**, 45, 481-7	2	1
26	Inhibition of human aldehyde oxidase activity by diet-derived constituents: structural influence, enzyme-ligand interactions, and clinical relevance. **2015**, 43, 34-41		22
25	Micropatterned coculture of hepatocytes on electrospun fibers as a potential in vitro model for predictive drug metabolism. **2016**, 63, 475-84		15
24	Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes. **2017**, 121, 239-245		10
23	ADME in Drug Discovery. **2017**, 39-67		7
22	Transporter effects on cell permeability in drug delivery. *Expert Opinion on Drug Delivery*, **2017**, 14, 385-401	4	15
21	Drug discovery. **2017**, 281-420		1
20	Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population. *Drug Metabolism and Pharmacokinetics*, **2018**, 33, 141-149	2.2	2
19	Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited. *Annual Review of Pharmacology and Toxicology*, **2019**, 59, 507-536	17.9	22
18	Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. *Xenobiotica*, **2019**, 49, 54-70	2	1
17	Characterization of metabolic activity, isozyme contribution and species differences of bavachin, and identification of efflux transporters for bavachin-O-glucuronide in HeLa1A1 cells. *Journal of Pharmacy and Pharmacology*, **2020**, 72, 1771-1786	4.8	4

16	In vitro characterization and in vitro to in vivo predictions of drug-drug interactions. **2020**, 273-309		
15	Case Study 4: Application of Basic Enzyme Kinetics to Metabolism Studies-Real-Life Examples. *Methods in Molecular Biology*, **2021**, 2342, 665-684	1.4	
14	Metabolism Studies in vitro and in vivo. **2006**, 493-520		5
13	Drug Discovery and Evaluation: Methods in Clinical Pharmacology. **2011**, 73-103		2
12	Drug Interactions. **2005**, 133-142		
11	In Vitro Inhibition with Botanical Products. *Drugs and the Pharmaceutical Sciences*, **2006**, 49-67		
10	Evaluating and Predicting Human Cytochrome P450 Enzyme Induction. 1		1
9	Utilization of In Vitro Cytochrome P450 Inhibition Data for Projecting Clinical Drug□Drug Interactions. 1		
8	Probe Cocktail Studies. **2011**, 631-653		
7	Systems Toxicology Modeling for Prediction in Humans.		
6	Case study 3. Application of basic enzyme kinetics to metabolism studies: real-life examples. *Methods in Molecular Biology*, **2014**, 1113, 441-60	1.4	
5	Probe Cocktail Studies. **2018**, 259-284		
4	Assessment of Drug-Drug Interactions of CC-90001, a Potent and Selective Inhibitor of c-Jun N-terminal Kinase.. *Xenobiotica*, **2022**, 1-29	2	1
3	The in vitro/in vivo metabolic pathways analysis of lobetyol, lobetyolin, and lobetyolinin, three polyacetylenes from Codonopsis Radix, by UHPLC-Q/TOF-MS and UHPLC-MS/MS. **2023**, 223, 115140		0
2	Drug discovery: Standing on the shoulders of giants. **2023**, 207-338		0
1	In Vitro Hepatic Models to Assess Herb□Drug Interactions: Approaches and Challenges. **2023**, 16, 409		0